Alliance for Regenerative Medicine

Alliance for Regenerative Medicine filed a Q2 report for Alliance for Regenerative Medicine on July 17, 2026.

Lobbying for Alliance for Regenerative Medicine · Advocacy organization supporting advances in regenerative medicine.

As filed: ALLIANCE FOR REGENERATIVE MEDICINE for ALLIANCE FOR REGENERATIVE MEDICINE.

All filings by Alliance for Regenerative Medicine · Everything Alliance for Regenerative Medicine has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 17, 2026

Expenses

$120,000

What this organization spent lobbying with its own staff. Reported using IRS section 162(e) definitions (method C): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products; FDA appropriations and staffing, specifically at CBER and OT; FDA oversight, including adaptive regulatory pathways for cell and gene therapies; Value-based payment legislation and related CMS regulations; Biologics regulation; Prescription Drug User Fee Act (PDUFA); Medicaid; Medicare; NIH appropriations; HHS oversight; HHS staffing and OPM issues; Federal support of medical research; Pharmaceutical tariffs; Biotechnology manufacturing.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.